A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Bimagrumab (Primary)
- Indications Muscular atrophy
- Focus Therapeutic Use
- Sponsors Novartis
- 10 May 2017 Planned End Date changed from 1 Jul 2018 to 30 Oct 2018.
- 10 May 2017 Planned primary completion date changed from 1 Jul 2018 to 30 Oct 2018.
- 26 Oct 2016 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.